Concepedia

Kingsley H. Nelson

KH

Statistics

Publications

6

Citations

226

H-Index

6

Active since

1997

Affiliations

Scynexis (United States)(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Yale University

Kingsley H. Nelson is an author at Scynexis (United States) specializing in medicinal chemistry, drug discovery, and pharmacology.

Publications per year

1997–2020

6

Publications

6

Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor

James M. Apgar, Robert R. Wilkening, Dann L. Parker et al. · Bioorganic & Medicinal Chemistry Letters · 2020 · 50 citations

, , +4

Synthesis and structure–activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists

J. Robert Merritt, Laura L. Rokosz, Kingsley H. Nelson et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 47 citations · Full text

, , +10

A chemoselective rhodium(II) mediated solid phase 1,3-dipolar cycloaddition and its application to a thermally self-cleaving furan scaffold

Darren L. Whitehouse, Kingsley H. Nelson, Sergey N. Savinov et al. · Tetrahedron Letters · 1997 · 43 citations · Full text

, , +17

Synthesis and biological evaluation of antifungal derivatives of enfumafungin as orally bioavailable inhibitors of β-1,3-glucan synthase

Brian Heasley, Gregory J. Pacofsky, Ahmed Mamai et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 34 citations

, , +16

Novel orally active inhibitors of β-1,3-glucan synthesis derived from enfumafungin

James M. Apgar, Robert R. Wilkening, Mark L. Greenlee et al. · Bioorganic & Medicinal Chemistry Letters · 2015 · 33 citations · Full text

, , +11

1–5 of 6